<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925130</url>
  </required_header>
  <id_info>
    <org_study_id>38RC14339</org_study_id>
    <nct_id>NCT02925130</nct_id>
  </id_info>
  <brief_title>Beta2-mimetic and Central Nervous System</brief_title>
  <acronym>BETACTIV</acronym>
  <official_title>Beta2-mimetic and Central Nervous System: Effects of Salbutamol on Cortical Excitability and Cerebral Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta2-mimetics such as Salbutamol have been shown to have ergogenic effects. Acute and
      chronic inhaled or oral doses of Salbutamol have been shown to increase whole body exercise
      and muscle performances. The underlying mechanisms are however unclear. Some data suggest
      that Salbutamol may have some effects on the central nervous system which may explain the
      improved exercise and neuromuscular performances. The present study aims to assess the
      effects of acite inhaled or oral Salbutamol intake on the neuromuscular system by using
      neurostimulation techniques and magnetic resonance imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of Salbutamol intake will be assessed by using transcranial magnetic stimulation
      on one hand and magnetic resonance imaging on the other hand. Maximal voluntary activation
      and cerebral activation will be measured during motor tasks performed until exhaustion after
      acute inhaled slabutamol intake, acture oral salbutamol intake or oral placebo intake.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">September 28, 2017</completion_date>
  <primary_completion_date type="Actual">September 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal voluntary activation</measure>
    <time_frame>Measured immediatly after treatment intake (within 1 h)</time_frame>
    <description>Measurement performed by using transcranial magnetic stimulation, superimposed on submaximal and maximal quadricep contractions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cortical activation</measure>
    <time_frame>Measured immediatly after treatment intake (within 1 h)</time_frame>
    <description>Measurement performed by using magnetic resonance imaging and the intensity of the BOLD signal in response to a motor task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise endurance</measure>
    <time_frame>Measured immediatly after treatment intake (within 1 h)</time_frame>
    <description>Time to exhaustion during the exercise muscle test.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Adrenergic Beta-2 Agonist Effect</condition>
  <condition>Albuterol Effect</condition>
  <arm_group>
    <arm_group_label>Inhaled Salbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute inhalation of 800 microgram Salbutamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Salbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute oral intake of 4 mg Salbutamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acute oral intake of a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.</description>
    <arm_group_label>Inhaled Salbutamol</arm_group_label>
    <arm_group_label>Oral Salbutamol</arm_group_label>
    <other_name>Albuterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acute oral intake of a placebo drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Albuterol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects without respiratory and cordiovascular diseases

          -  Male

          -  Age between 18 and 35

          -  Trained subjects (&gt;6 hours of physical activity per week)

          -  Non- or ex-smoker (smoking cessation since at least 1 year)

        Exclusion Criteria:

          -  Respiratory, cardiovascular and metabolic diseases

          -  Neuromuscular diseases

          -  thyrotoxicosis, or diabetes treated with insulin

          -  alcoholism

          -  MRI contraindication

          -  TMS contraindication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Guinot, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

